PMID- 18720692
OWN - NLM
STAT- MEDLINE
DCOM- 20081103
LR  - 20151119
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 7
IP  - 8
DP  - 2008 Aug
TI  - Evaluating the tolerability and efficacy of etanercept compared to triamcinolone 
      acetonide for the intralesional treatment of keloids.
PG  - 757-61
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory and 
      profibrotic cytokine that inhibits degradation of collagen and 
      glycosaminoglycans. Etanercept, a recombinant TNF-alpha receptor fusion protein, 
      may decrease excessive fibrous tissue in keloids. OBJECTIVE: To evaluate the 
      tolerability and efficacy of etanercept as compared to triamcinolone acetonide 
      (TAC) for the treatment of keloids. METHODS: Twenty subjects were randomly 
      assigned to receive monthly intralesional injections of either 25 mg of 
      etanercept or 20 mg of TAC for 2 months. Keloids were evaluated at baseline, week 
      4, and week 8 by subjects and investigators in a blinded fashion using physical, 
      clinical, and cosmetic parameters. Photographs were taken and adverse events were 
      noted during each evaluation. RESULTS: Etanercept improved 5/12 parameters 
      including significant pruritus reduction, while TAC improved 11/12 parameters at 
      week 8, although no statistical difference was observed as compared to baseline. 
      There was no significant difference between the 2 treatment groups. Both 
      treatments were safe and well tolerated. CONCLUSION: Etanercept was safe, well 
      tolerated, improved several keloid parameters, and reduced pruritus to a greater 
      degree than TAC therapy. However, further studies are required before it can be 
      recommended for the treatment of keloids.
FAU - Berman, Brian
AU  - Berman B
AD  - University of Miami, Miller School of Medicine, Department of Dermatology and 
      Cutaneous Surgery, Miami, FL 33136, USA. bberman@med.miami.edu
FAU - Patel, Jitendrakumar K
AU  - Patel JK
FAU - Perez, Oliver A
AU  - Perez OA
FAU - Viera, Martha H
AU  - Viera MH
FAU - Amini, Sadegh
AU  - Amini S
FAU - Block, Samantha
AU  - Block S
FAU - Zell, Deborah
AU  - Zell D
FAU - Tadicherla, Sujatha
AU  - Tadicherla S
FAU - Villa, Adriana
AU  - Villa A
FAU - Ramirez, Claudia
AU  - Ramirez C
FAU - De Araujo, Tami
AU  - De Araujo T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - F446C597KA (Triamcinolone Acetonide)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Acne Keloid/*drug therapy/pathology
MH  - Adult
MH  - Anti-Inflammatory Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Etanercept
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/administration & dosage/adverse effects/*therapeutic use
MH  - Injections
MH  - Male
MH  - Middle Aged
MH  - Pruritus/drug therapy/etiology
MH  - Receptors, Tumor Necrosis Factor/administration & dosage/*therapeutic use
MH  - Skin/pathology
MH  - Triamcinolone Acetonide/administration & dosage/adverse effects/*therapeutic use
EDAT- 2008/08/30 09:00
MHDA- 2008/11/04 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2008/11/04 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
PST - ppublish
SO  - J Drugs Dermatol. 2008 Aug;7(8):757-61.